Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Launched by BRUCE ROBINSON, MD · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to treat certain types of skin cancer, specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The researchers are looking at a combination of fractional laser therapy and an ointment called tirbanibulin to see if it can effectively treat these cancers without the need for more invasive surgery. The trial will involve using special lasers on the skin and then having patients apply the ointment for five nights afterward. The goal is to improve treatment outcomes while also helping patients maintain a better cosmetic appearance.

To be eligible for this trial, participants should be between the ages of 65 and 74 and must have a confirmed diagnosis of BCC or SCC that hasn't been treated before. It's important to note that pregnant individuals cannot participate in this study. If you decide to join, you can expect to receive the laser treatment followed by the ointment application, and the hope is that this approach will offer a less invasive option for managing skin cancer.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method.
• Exclusion Criteria:
• • Cannot be pregnant at the time of treatment